Clinical Trial Update: Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial of talimogene laherparepvec (T-VEC) in locally advanced cutaneous angiosarcoma was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma of the Skin

Drugs mentioned

• Talimogene laherparepvec (T-VEC) (talimogene laherparepvec)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Angiosarcoma of Skin | Phase 2 | Status: TERMINATED | Results posted: 2022-11-01